Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 52, 2022 - Issue 2
175
Views
1
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Bioavailability, safety and tolerability of intravenous brivaracetam in healthy Japanese participants

, & ORCID Icon
Pages 146-151 | Received 08 Jan 2022, Accepted 14 Mar 2022, Published online: 28 Mar 2022
 

Abstract

  1. We characterised the bioavailability, safety, and tolerability of brivaracetam 100 mg intravenous bolus and 15-min infusion versus oral reference tablet in 24 healthy Japanese participants.

  2. In this randomised, open-label, three-period crossover study, participants received three 100 mg single doses of brivaracetam, intravenous bolus, infusion, and oral tablets. Maximum plasma concentration (Cmax), area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUCt), and area under the plasma concentration-time curve extrapolated to infinity (AUCinf), were compared using analysis of variance following logarithmic transformation. Bioavailability comparisons were based on the 90% confidence intervals (CIs) around the geometric least squares means ratios (intravenous:oral). Safety and tolerability were monitored throughout the study.

  3. The 90% CIs around AUCt and AUCinf ratios were entirely contained within the bioequivalence limits (0.80–1.25), but Cmax was outside the limits (90% CI: 1.77–2.08 and 1.44–1.70 for intravenous bolus and infusion, respectively). All participants completed the study. Brivaracetam was well tolerated.

  4. Because response to brivaracetam in epilepsy is related to exposure (AUC), no dose adjustment is warranted when switching from oral to intravenous dosing. However, investigations are needed to assess the safety and tolerability of intravenous administration in Japanese patients with epilepsy.

Acknowledgements

The authors thank Yoichiro Ogama (Souseikai Sumida Hospital, Tokyo, Japan), for conducting the clinical trial as principal investigator, Yoshihiro Muramoto (UCB Pharma, Tokyo, Japan) for statistical support, and Jeffrey Long (UCB Pharma, Brussels, Belgium) and Giulia Leonetti (PRA Health Sciences, Assen, The Netherlands) for bioanalytical support. The authors acknowledge Kyoko Hirano, CMPP (UCB Pharma, Tokyo, Japan) for publication coordination and Aramedic Co., Ltd. for writing support, which was funded by UCB Pharma.

Disclosure statement

This study was supported by UCB Pharma, which was responsible for the design and conduct of the study, and collection, management, and analysis of the data. All authors were employed by UCB Pharma when the study was performed. The authors had final responsibility for the content.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 897.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.